About 1ST Biotherapeutics
1ST Bio is dedicated to developing breakthrough therapies with a key value to provide novel medicines to patients. We are focused on discovery and development of innovative first-in-class therapeutic candidates with highly likelihood of clinical success.
Founder and CEO: Jamie Jae Eun Kim
3 articles with 1ST Biotherapeutics
1ST Biotherapeutics and twoXAR Advance Three Novel Glioblastoma Treatment Candidates into In Vivo Testing in Less Than One Year
Partnership Combines Shared Drug Discovery Expertise with Integrated Artificial Intelligence to Identify Promising Targets in Half the Time of Traditional R&D Approaches
1ST Biotherapeutics and twoXAR Form Co-Development Collaboration to Discover and Develop Treatments for Glioblastoma
1ST Biotherapeutics, Inc. and twoXAR, Inc. today announced an agreement to jointly discover and develop novel, efficacious treatments to address unmet medical needs in glioblastoma multiforme (“glioblastoma”).
1ST Bio today announced a collaboration to co-develop novel brain penetrant c-Abl inhibitors for Parkinson's disease.